

DAFTAR PUSTAKA

- Adwan, M. 2019. 'Clinical and Serologic Characteristics of Systemic Lupus Erythematosus in the Arab World: A Pooled Analysis of 3,273 Patients'. *Archives of Rheumatology*, 33(4), 455–463.
- Anić, F., Zuvčić-Butorac, M., Stimac, D., dan Novak, S. 2014. 'New classification criteria for systemic lupus erythematosus correlate with disease activity'. *Croatian Medical Journal*, 55(5), 514–519.
- Bashal, F. 2013. 'Hematological Disorders in Patients with Systemic Lupus Erythematosus'. *The Open Rheumatology Journal*, 7(1), 87–95.
- Bengtsson, A. A., Rylander, L., Hagmar, L., Nived, O., dan Sturfelt, G. 2002. 'Risk factors for developing systemic lupus erythematosus : a case – control study in southern Sweden'. *British Society for Rheumatology*, 41, 563–571.
- Bertsias, G., Cervera, R., dan T Boumpas, D. 2015. 'Systemic Lupus Erythematosus: Pathogenesis and Clinical Features'. *EULAR Textbook on Rheumatic Diseases, 1909*, 476–505.
- Chaiamnuay, S., Lomaratana, V., Sumransurp, S., Phukongchai, S., Narongroeknawin, P., dan Asavatanabodee, P. 2010. 'Health related quality of life and disease severity of SLE patients in Phramongkutklao Hospital'. *J Med Assoc Thai*.
- Choi, J., Kim, S. T., dan Craft, J. 2013. 'The Pathogenesis of SLE - an Update'. *Curr Opin Immunol*, 24(6), 651–657.
- Cojocaru, M., Cojocaru, I. M., Silosi, I., dan Vrabie, C. D. 2011. 'Manifestations of systemic lupus erythematosus'. *Maedica*, 6(4), 330–336.
- Dahlan, M. S. 2011. 'Statistik Untuk Kedokteran Dan Kesehatan' (3rd ed.). *Salemba*

Medika.

- Fanouriakis, A., dan Bertsias, G. 2019. 'Changing paradigms in the treatment of systemic lupus erythematosus'. *Lupus Science and Medicine*, 6(1), 1–10.
- Feld, J., dan Isenberg, D. 2014. 'Why and how should we measure disease activity and damage in lupus?'. *Presse Medicale*, 43(6P2).
- Forbess, L. J., Rossides, M., Weisman, M. H., dan Simard, J. F. 2019. 'New-onset non-infectious pulmonary manifestations among patients with systemic lupus erythematosus in Sweden'. *Arthritis Research and Therapy*, 21(1), 4–9.
- Gandino, I. J., Scolnik, M., Bertiller, E., Scaglioni, V., Catoggio, L. J., dan Soriano, E. R. 2017. 'Complement levels and risk of organ involvement in patients with systemic lupus erythematosus'. *Lupus Science and Medicine*, 4(1), 1–5.
- Hikmah, Z., dan Prihaningtyas, R. A. 2018. 'Bersahabat dengan lupus: kupas tuntas SLE pada anak'. *PT Gramedia*.
- Hospital for Special Surgery. 2015. 'Understanding Lupus Lab Tests and Results for Lupus (SLE)'. https://www.hss.edu/conditions_understanding-laboratory-tests-and-results-for-systemic-lupus-erythematosus.asp
- Hu, C. L., dan Peng, K. L. 2014. 'Bilateral macular infarction as an ocular manifestation of systemic lupus erythematosus (SLE)'. *Clinical Ophthalmology*, 8, 1845–1848.
- Judha, M., dan Setiawan, D. I. (2015). 'Apa dan Bagaimana Penyakit Lupus? (Sistemik Lupus Eritematosus)' (1st ed.). *Gosyen Publishing*.
- Kementrian Kesehatan. 2017. 'Infodatin situasi lupus di indonesia 2017'. *Pusat Data dan Informasi Kementrian Kesehatan RI*.
- Kim, A. H. J., Strand, V., Sen, D. P., Fu, Q., Mathis, N. L., Schmidt, M. J., Bruchas, R. R., Staten, N. R., Olson, P. K., Stiening, C. M., dan Atkinson, J. P. 2019.

- 'Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity'. *Arthritis and Rheumatology*, 71(3), 420–430.
- Kuhn, A., Bonsmann, G., Anders, H., Herzer, P., Tenbrock, K., dan Schneider, M. (2015). 'The Diagnosis and Treatment of Systemic Lupus Erythematosus'.
- Li, W., Li, H., Song, W., Hu, Y., Liu, Y., Da, R., Chen, X., Li, Y., Ling, H., Zhong, Z., dan Zhang, F. 2013. 'Differential diagnosis of systemic lupus erythematosus and rheumatoid arthritis with complements C3 and C4 and C-reactive protein'. *Experimental and Therapeutic Medicine*, 6(5), 1271–1276.
- Lipsky, P. E. 2001. 'Systemic lupus erythematosus : an autoimmune disease of B cell hyperactivity'. *Nature Publishing*.
- Maidhof, W., dan Hilas, O. 2012. 'Lupus: an overview of the disease and management options'. *P & T: A Peer-Reviewed Journal for Formulary Management*, 37(4), 240–249.
- Marc, D., dan Olson, K. 2009. 'Hypersensitivity Reactions and Methods of Detection'. *NeuroScience, Inc*, 1–4.
- Medlin, J. L., Hansen, K. E., Fitz, S. R., dan Bartels, C. M. 2016. 'A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus'. *Seminars in Arthritis and Rheumatism*, 45(6), 691–697.
- Mikdashi, J., dan Nived, O. 2015. 'Measuring disease activity in adults with systemic lupus erythematosus: The challenges of administrative burden and responsiveness to patient concerns in clinical research'. *Arthritis Research and Therapy*, 17(1), 1–10.
- Mohamed, A. A. A., Hammam, N., EL Zohri, M. H., dan Gheita, T. A. 2019. 'Cardiac

- Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features'. *BioMed Research International*, 2019, 1–8.
- Mosca, M., Merrill, J. T., dan Bombardieri, S. 2007. 'Assessment of Disease Activity in Systemic Lupus Erythematosus'. *Systemic Lupus Erythematosus: A Companion to Rheumatology* (First Edit). Elsevier Inc.
- Narayanan, K., Marwaha, V., Shanmuganandan, C. K., dan Shankar, S. 2010. 'Correlation between systemic lupus erythematosus disease activity index, C3, C4 and anti-dsDNA antibodies'. *Medical Journal Armed Forces India*, 66(2), 102–107.
- Qu, C., Zhang, J., Zhang, X., Du, J., Su, B., dan Li, H. 2018. 'Value of combined detection of anti nuclear antibody, anti double stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus'. *Experimental and Therapeutic Medicine*, 1390–1394.
- Ramos, P. S., Brown, E. E., Kimberly, R. P., dan Langefeld, C. D. 2010. 'Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis'. *Seminars in Nephrology*, 30(2), 164–176.
- Rheumatol. 2017. 'What is it ? A Tool to Assess Disease Activity in Patients with SLE SELENA-SLEDAI' (Vol. 66, Issue suppl III). *GSK group of companies or its licensor*.
- Salleh, M. R. 2008. 'Life event, stress and illness'. *Malaysian Journal of Medical Sciences*, 15(4), 9–18.
- Sandhu, V., dan Quan, M. 2017. 'SLE and Serum Complement: Causative, Concomitant or Coincidental?'. *The Open Rheumatology Journal*, 11, 113–122.
- Senaldi, G., Makinde, V. A., Vergani, D., dan Isenberg, D. A. 1988. 'Correlation of

- the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus'. *Annals of the Rheumatic Diseases*, 47(11), 913–917.
- Sutcliffe, N., Clarke, A., evinton, C., Frost, C., Gordon, C., dan Isenberg, D. 1999. 'Associates of health status in patients with systemic lupus erythematosus - PubMed'. *J Rheumatol*.
- Thakral, A., dan Klein-Gitelman, M. S. 2016. 'An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus'. *Rheumatology and Therapy*, 3(2), 209–219.
- The Lupus Foundation of America. 2013. 'Understanding Lupus | Lupus Foundation of America'. <https://www.lupus.org/understanding-lupus>
- Tseng, M.-H., Lin, S.-H., Wu, C.-Y., Chien, H.-P., Yang, H.-Y., Chen, Y.-C., Chou, Y.-C., dan Huang, J.-L. 2018. 'Serum complement factor I is associated with disease activity of systemic lupus erythematosus'. *Oncotarget*, 9(9), 8502–8511.
- Walport, M. J. 2002. 'Complement and systemic lupus erythematosus'. *Arthritis Research*, 4 Suppl 3(Suppl 3), S279-93.
- Weckerle, C. E., dan Niewold, T. B. 2011. 'The unexplained female predominance of systemic lupus erythematosus: Clues from genetic and cytokine studies'. *Clinical Reviews in Allergy and Immunology*, 40(1), 42–49.
- Yuan, Y., Zhao, L., Ye, Z., Ma, H., Wang, X., dan Jiang, Z. 2019. 'Association of toll-like receptor 9 expression with prognosis of systemic lupus erythematosus'. *Experimental and Therapeutic Medicine*, 3247–3254.
- Zvezdanovic, L., Dordevic, V., Cosic, V., Cvetkovic, T., Kundalic, S., dan Stankovic, A. 2006. 'The significance of cytokines in diagnosis of autoimmune diseases'. *Jugoslov Med Biohem*, 25, 363–372.